FORE Biotherapeutics announced the closing of an upsized $67.4 million Series D-2 extension financing, co-led by SR One, Medicxi and SymBiosis, bringing the total amount raised under the Series D-2 to $110 million. New investors including LG Technology Ventures, Primer Ventures and Axil joined a syndicate of existing backers -- OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung and 3B Capital -- in the extension round.
The capital is earmarked specifically for continued late-stage development of plixorafenib, FORE's lead drug candidate targeting BRAF-mutated cancers. The company's FORTE study includes a basket focused on recurrent or progressive BRAF V600E primary central nervous system tumors, and FORE says it has already reached its target enrollment of approximately 50 patients in that basket, with topline data now anticipated around the end of 2026.
If that data reads out favorably, FORE is targeting a regulatory submission to the FDA under the Accelerated Approval pathway in 2027 -- a timeline the fresh capital is specifically designed to fund through, covering the CNS basket readout, the subsequent regulatory submission process, and continued development in additional distinct indications including rare BRAF V600-mutated solid tumors and advanced solid tumors with BRAF fusions.
“The capital is earmarked specifically for continued late-stage development of plixorafenib, FORE's lead drug candidate targeting BRAF-mutated cancers.”
Extension financings like this one have become a common bridge mechanism for late-stage biotech companies that want to fund a specific near-term data catalyst without pursuing a full IPO in an uncertain public-market window, or without diluting existing shareholders at a potentially depressed pre-data valuation. FORE's approach -- raising specifically to fund through a defined, near-term clinical readout -- is a more conservative capital strategy than companies opting to IPO ahead of major data, a path Apnimed and Scribe Therapeutics are each taking with their own current Nasdaq filings.
For biotech founders, FORE's upsized extension is a useful data point on investor appetite: existing backers were willing to not just maintain but expand their exposure ahead of a defined 2026 data catalyst, rather than waiting for the readout to reprice the company. For investors, BRAF-targeted therapies remain a competitive but clinically validated oncology category, and FORE's CNS-specific basket addresses a genuine unmet need given how few BRAF-targeted drugs have shown activity against brain tumors specifically.
The bear case: extension financings, however well-subscribed, are still a signal that a company needed additional runway beyond its original raise to reach its next value-inflection point, and a disappointing CNS basket readout at the end of 2026 would leave FORE needing to raise again from a materially weaker negotiating position. What to watch next: the FORTE study's CNS tumor basket topline data expected around year-end, and whether FORE pursues an IPO or a strategic partnership once that data is in hand.